Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 71

Similar articles for PubMed (Select 22690479)

1.

[Cutaneous adverse effects of TNFalpha antagonists].

Failla V, Sabatiello M, Lebas E, de Schaetzen V, Dezfoulian B, Nikkels AF.

Rev Med Liege. 2012;67 Spec No:3-7. French.

PMID:
22690479
2.
3.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
4.

Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists.

Lamrock E, Brown P.

Australas J Dermatol. 2012 Nov;53(4):e87-90. doi: 10.1111/j.1440-0960.2011.00863.x. Epub 2012 Feb 16. Review.

PMID:
23157794
5.

Cutaneous adverse effects of biological therapies for psoriasis.

Roé E, Puig L, Corella F, García-Navarro X, Alomar A.

Eur J Dermatol. 2008 Nov-Dec;18(6):693-9. doi: 10.1684/ejd.2008.0521. Epub 2008 Oct 27.

PMID:
18955203
6.

[Cutaneous events during anti-TNF alpha therapy: a prospective observational study of 41 cases].

Bonnet N, Guis S, Koeppel MC, Roudier J, Grimaud JC, Jean-Pastor MJ, Berbis P.

Ann Dermatol Venereol. 2010 Jan;137(1):12-20. doi: 10.1016/j.annder.2009.12.003. Epub 2009 Dec 31. French.

PMID:
20110063
7.

Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.

Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L.

J Crohns Colitis. 2013 Nov 1;7(10):769-79. doi: 10.1016/j.crohns.2013.01.009. Epub 2013 Mar 1. Review.

8.
9.
10.

Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review.

Toussirot E, Streit G, Wendling D.

Recent Pat Inflamm Allergy Drug Discov. 2007 Feb;1(1):39-47. Review.

PMID:
19075965
11.

[Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases].

Lebas D, Staumont-Sallé D, Solau-Gervais E, Flipo RM, Delaporte E.

Ann Dermatol Venereol. 2007 Apr;134(4 Pt 1):337-42. French.

PMID:
17483752
12.

Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review.

Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ.

J Am Acad Dermatol. 2009 Sep;61(3):486-504. doi: 10.1016/j.jaad.2008.10.060. Epub 2009 Jul 22. Review.

PMID:
19628303
13.

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.

Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Assche G, Vermeire S, Rutgeerts P.

Gut. 2009 Apr;58(4):501-8. doi: 10.1136/gut.2008.163642. Epub 2008 Oct 2.

PMID:
18832524
14.

[Infectious risk].

Calabuig E, Salavert M.

Actas Dermosifiliogr. 2008 Jul;99 Suppl 4:14-22. Spanish.

PMID:
19080987
15.

[Off-label use of infliximab].

Onder M, Salavastru C, Fritz K.

Hautarzt. 2013 Oct;64(10):757-61. doi: 10.1007/s00105-013-2596-z. Review. German.

PMID:
24150825
16.

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.

Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN Jr, Braun MM.

Arthritis Rheum. 2002 Oct;46(10):2565-70.

17.

[Cutaneous lupus induced by etanercept in rheumatoid arthritis].

Abourazzak FE, Guggenbuhl P, Perdriger A, Meadeb J, Gando-Cocley N, Chevrant-Breton J, Hajjaj-Hassouni N, Chalès G.

Rev Med Interne. 2008 Sep;29(9):744-7. doi: 10.1016/j.revmed.2008.06.003. Epub 2008 Aug 3. French.

PMID:
18676065
18.
19.

TNFalpha as therapeutic target: new drugs, more applications.

Reimold AM.

Curr Drug Targets Inflamm Allergy. 2002 Dec;1(4):377-92. Review.

PMID:
14561184
20.

Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases.

LaDuca JR, Gaspari AA.

Dermatol Clin. 2001 Oct;19(4):617-35. Review.

PMID:
11705350
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk